Daniel J Gibson

Author:

Daniel Gibson

ISBN #:

0312207778

US Patent:

20110053272, Mar 3, 2011

Filed:

Mar 5, 2010

Appl. No.:

12/718911

Inventors:

Gwynedd A. Benders - Portland OR, US
John I. Glass - Germantown MD, US
Carole Lartigue - Des Arenes Bayonne, FR
Sanjay Vashee - Boyds MD, US
Mikkel A. Algire - Jessup MD, US
Hamilton O. Smith - San Diego CA, US
Charles E. Merryman - Sykesville MD, US
Vladimir N. Noskov - Montgomery Village MD, US
Ray-Yuan Chuang - Rockville MD, US
Daniel G. Gibson - Crofton MD, US
J. Craig Venter - La Jolla CA, US

International Classification:

C12N 15/74
C12N 15/82
C12N 15/85
C12N 1/21
C12N 1/15
C12N 1/19
C12N 5/10

US Classification:

435455, 435471, 435468, 4352523, 43525411, 4352542, 435419, 435348, 435325

Abstract:

Compositions and methods are disclosed herein for cloning a donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.

US Patent:

20110053273, Mar 3, 2011

Filed:

May 19, 2010

Appl. No.:

12/783489

Inventors:

Gwynedd A. Benders - Portland OR, US
John I. Glass - Germantown MD, US
Clyde A. Hutchison - La Jolla CA, US
Carole Lartigue - Des Arenes Bayonne, FR
Sanjay Vashee - Boyds MD, US
Mikkel A. Algire - Jessup MD, US
Hamilton O. Smith - San Diego CA, US
Charles E. Merryman - Sykesville MD, US
Vladimir N. Noskov - Montgomery Village MD, US
Ray-Yuan Chuang - Rockville MD, US
Daniel G. Gibson - Crofton MD, US
J. Craig Venter - La Jolla CA, US

Assignee:

Synthetic Genomics, Inc. - La Jolla CA

International Classification:

C12N 15/87
C12N 1/21

US Classification:

435455, 435471, 435468, 4352523

Abstract:

Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.

US Patent:

20210213362, Jul 15, 2021

Filed:

Mar 1, 2021

Appl. No.:

17/249379

Inventors:

- Redwood City CA, US
Daniel Valentine Gibson - Irvine CA, US
Kenneth Alan Moss - Redwood City CA, US

International Classification:

A63F 13/795
A63F 13/61

Abstract:

Embodiments of the systems and methods disclosed herein provide a sponsor matching system in which players and sponsors can be matched. Upon a match based at least in part on stored sponsorship criteria and/or player preferences, a first sponsor can select a set of players to receive permission to select an advertisement associated with the first sponsor. Once a first player of the selected players selects an advertisement and an advertisement placement location associated with the first sponsor, the sponsor matching system can generate game rendering instructions for a first player system associated with the first player.

US Patent:

20200306645, Oct 1, 2020

Filed:

Mar 29, 2019

Appl. No.:

16/370846

Inventors:

- Redwood City CA, US
Daniel Valentine Gibson - Irvine CA, US
Kenneth Alan Moss - Redwood City CA, US

International Classification:

A63F 13/795
A63F 13/61

Abstract:

Embodiments of the systems and methods disclosed herein provide a sponsor matching system in which players and sponsors can be matched. Upon a match based at least in part on stored sponsorship criteria and/or player preferences, a first sponsor can select a set of players to receive permission to select an advertisement associated with the first sponsor. Once a first player of the selected players selects an advertisement and an advertisement placement location associated with the first sponsor, the sponsor matching system can generate game rendering instructions for a first player system associated with the first player.

US Patent:

20190177759, Jun 13, 2019

Filed:

Dec 6, 2018

Appl. No.:

16/212534

Inventors:

- La Jolla CA, US
Jun Urano - Irvine CA, US
Nicky C. Caiazza - Rancho Santa Fe CA, US
Daniel G. Gibson - Carlsbad CA, US

International Classification:

C12P 19/34
C12N 15/10
C12Q 1/6844

Abstract:

The present invention discloses methods for assembling a nucleic acid molecule from a set of overlapping oligonucleotides. The method involves contacting a set of overlapping oligonucleotides with a DNA polymerase, a mixture of dNTPs, and a crowding agent to form an assembly mixture. In one embodiment the crowding agent is polyethylene glycol (PEG). The presence of the crowding agent facilitates the nucleic acid assembly process of the invention. The assembly mixture is then subjected to multiple cycles, each cycle comprising an annealing phase, an extension phase, and a denaturation phase, and the desired nucleic acid molecule is thereby assembled. In some embodiments one or more of the phases are time varied.

US Patent:

20140308710, Oct 16, 2014

Filed:

Dec 11, 2013

Appl. No.:

14/103578

Inventors:

- La Jolla CA, US
Jun Urano - Irvine CA, US
Nicky C. Caiazza - Rancho Santa Fe CA, US
Daniel G. Gibson - Carlsbad CA, US

Assignee:

Synthetic Genomics, Inc. - La Jolla CA

International Classification:

C12P 19/34

US Classification:

435 912

Abstract:

The present invention discloses methods for assembling a nucleic acid molecule from a set of overlapping oligonucleotides. The method involves contacting a set of overlapping oligonucleotides with a DNA polymerase, a mixture of dNTPs, and a crowding agent to form an assembly mixture. In one embodiment the crowding agent is polyethylene glycol (PEG). The presence of the crowding agent facilitates the nucleic acid assembly process of the invention. The assembly mixture is then subjected to multiple cycles, each cycle comprising an annealing phase, an extension phase, and a denaturation phase, and the desired nucleic acid molecule is thereby assembled. In some embodiments one or more of the phases are time varied.